A Randomized Trial of Combination Anastrozole plus Gefitinib and of Combination Fulvestrant plus Gefitinib in the Treatment of Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer

INTRODUCTION: EGFR signalling pathways appear involved in endocrine therapy resistance in breast cancer. This trial estimates the antitumor efficacy and toxicity of the EGFR tyrosine kinase inhibitor gefitinib in combination with anastrozole or fulvestrant in postmenopausal hormone receptor positive...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Carlson, Robert W., O'eill, Anne, Vidaurre, Tatiana, Gomez, Henry L., Badve, Sunil S., Sledge, George W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3587179/
https://ncbi.nlm.nih.gov/pubmed/22418699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-012-1997-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados